1 not yet recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow SKB315 for injection: new trials by email Literature Review of SKB315 for injection trials Research Report on SKB315 for injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma Tislelizumab, SKB315 for injection, Capecitabine - Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-06-30 | 2026-05-27 |
| A Study of SKB315 in Patients With Advanced Solid Tumors SKB315 for injection, Drug: Tagitanlimab Drug: Capecitabine - Advanced Solid Tumors | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 246 | 2022-03-16 | 2026-05-08 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (2)
China (2)
Yi Ba, Professor (1) · Yi Ba, professor (1)